2020 ESE声明:COVID-19和内分泌疾病

2020-04-11 欧洲内分泌学会 Endocrine. 2020 Apr 11.

2020年4月,欧洲内分泌学会(ESE)发布了COVID-19和内分泌疾病的声明,文章主要介绍了COVID-19感染的症状,糖尿病患者其他内分泌疾病患者预防COVID-19感染,以及疑似感染的管理的处

中文标题:

2020 ESE声明:COVID-19和内分泌疾病

英文标题:

COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology.

发布机构:

欧洲内分泌学会

发布日期:

2020-04-11

简要介绍:

2020年4月,欧洲内分泌学会(ESE)发布了COVID-19和内分泌疾病的声明,文章主要介绍了COVID-19感染的症状,糖尿病患者其他内分泌疾病患者预防COVID-19感染,以及疑似感染的管理的处理。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 ESE声明:COVID-19和内分泌疾病.pdf)] GetToolGuiderByIdResponse(projectId=1, id=7c21e1c00189618c, title=2020 ESE声明:COVID-19和内分泌疾病, enTitle=COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology., guiderFrom=Endocrine. 2020 Apr 11., authorId=0, author=, summary=2020年4月,欧洲内分泌学会(ESE)发布了COVID-19和内分泌疾病的声明,文章主要介绍了COVID-19感染的症状,糖尿病患者其他内分泌疾病患者预防COVID-19感染,以及疑似感染的管理的处, cover=https://img.medsci.cn/2020426/1587912001514_2020535.jpg, journalId=0, articlesId=null, associationId=916, associationName=欧洲内分泌学会, associationIntro=欧洲内分泌学会(The European Society of Endocrinology,ESE)是欧洲内分泌学者学习和交流的圣地,旨在通过组织会议、提供培训课程和出版物等方式,促进内分泌领域内公益性研究、教育和临床实践等项目,提高公众意识,并对相关法规的完善起到监督作用。ESE工作主要集中于以下方面:①举办欧洲内分泌会议(European Congress of Endocrinology,ECE),为业内人士交流最新成果和经验提供平台;②提供指南和政策,为临床医生和研究人员提供技术支持,如病人资料、培训课程等;③通过&ldquo;职业生涯&rdquo;栏目组建特别兴趣小组、欧洲青年内分泌科学家委员会、ESE护理小组等以便于会员之间交流合作等。ESE网站还有相关新闻、奖金、教育与科研、出版物以及媒体中心等栏目。, copyright=0, guiderPublishedTime=Sat Apr 11 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年4月,欧洲内分泌学会(ESE)发布了COVID-19和内分泌疾病的声明,文章主要介绍了COVID-19感染的症状,糖尿病患者其他内分泌疾病患者预防COVID-19感染,以及疑似感染的管理的处理。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=10098, tagName=内分泌疾病), TagDto(tagId=102190, tagName= COVID-19)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=10098, guiderKeyword=内分泌疾病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2471, appHits=33, showAppHits=0, pcHits=627, showPcHits=2471, likes=0, shares=0, comments=3, approvalStatus=1, publishedTime=Sun Apr 26 23:10:10 CST 2020, publishedTimeString=2020-04-11, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Apr 26 22:40:05 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 11:08:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ESE声明:COVID-19和内分泌疾病.pdf)])
2020 ESE声明:COVID-19和内分泌疾病.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=973486, encodeId=16f19e3486d8, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 16:54:28 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889802, encodeId=eedb889802d9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42705312246, createdName=1488d5e7m58暂无昵称, createdTime=Sat Oct 03 06:15:23 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809845, encodeId=8228809845bd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:03:40 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2021-06-14 ms8000000656093431

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=973486, encodeId=16f19e3486d8, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 16:54:28 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889802, encodeId=eedb889802d9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42705312246, createdName=1488d5e7m58暂无昵称, createdTime=Sat Oct 03 06:15:23 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809845, encodeId=8228809845bd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:03:40 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-10-03 1488d5e7m58暂无昵称

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=973486, encodeId=16f19e3486d8, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 16:54:28 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889802, encodeId=eedb889802d9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42705312246, createdName=1488d5e7m58暂无昵称, createdTime=Sat Oct 03 06:15:23 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809845, encodeId=8228809845bd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:03:40 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-17 ms5000002046462755

    0

拓展阅读

2018 EHRA意见书:内分泌疾病患者的心律失常管理和设备治疗

欧洲心律学会(EHRA,European Heart Rhythm Association) · 2018-03-16

2020 TES临床实践指南:内分泌疾病患者的血脂管理

美国内分泌学会(TES,The Endocrine Society) · 2020-12-01

2022 KES立场声明:免疫检查点抑制剂和内分泌疾病

韩国内分泌学会(KES,Korean Endocrine Society) · 2022-12-23

生酮饮食与慢性疾病的研究进展

暂未更新 · 2022-09-30